The purpose of this study is to allow patients with acromegaly, or their partners, to learn how to successfully inject Somatuline Autogel at home. Ability to perform unsupervised injections whilst maintaining adequate disease control will be assessed.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Michael White Centre Diabetes & Endocrinology, Hull Royal Infirmary
Hull, East Yorkshire, United Kingdom
Department of Endocrinology, The Royal Free Hospital
Hampstead, London, United Kingdom
Dept of Endocrinology, Aberdeen Royal Infirmary
Aberdeen, United Kingdom
To assess the ability of patients or their partners to perform unsupervised Somatuline Autogel injections.
To assess whether administration of unsupervised injections of Somatuline Autogel has any effect on GH and IGF-1 control or serum lanreotide levels.
To assess patient/partner and healthcare professional experience with unsupervised injections.
To assess the safety of patients or their partners performance of unsupervised Somatuline Autogel injections.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Department of Medicine, Queen Elizabeth Hospital
Birmingham, United Kingdom
Department of Endocrinology, Coventry & Warwickshire Hospital
Coventry, United Kingdom
Department of Endocrinology, Leicester Royal Infirmary
Leicester, United Kingdom
Department of Endocrinology, Manchester Royal Infirmary
Manchester, United Kingdom
The Oxford Centre for Diabetes, Endocrinology and Metabolism, The Churcill Hospital
Oxford, United Kingdom
Department of Endocrinology, Royal Hallamshire Hospital
Sheffield, United Kingdom
Department of Endocrinology, Sunderland Royal Hospital
Sunderland, United Kingdom